BIOCRYST PHARM
BIOCRYST PHARM operates in Diversified Metals & Mining.
BIOCRYST PHARM (BO1) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.018x
Based on the latest financial reports, BIOCRYST PHARM (BO1) has a cash flow conversion efficiency ratio of -0.018x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.24 Million) by net assets (€-468.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BIOCRYST PHARM - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how BIOCRYST PHARM's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BIOCRYST PHARM Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOCRYST PHARM ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RENT3F
SA:RENT3F
|
N/A |
|
Kyntra Bio, Inc.
NASDAQ:KYNB
|
-0.106x |
|
Argentum Silver Corp
PINK:AGSVF
|
0.135x |
|
INTL ZEOLITE
F:ZEON
|
N/A |
|
A S CREATION TAP N - Dusseldorf Stock Exchang
DU:ACWN
|
0.013x |
|
Syncona Limited
LSE:SYNC
|
0.006x |
|
Samsung Special Purpose Acquisition 8 Co.
KO:448740
|
N/A |
|
EGAIN - Frankfurt Stock Exchang
F:EGCA
|
0.017x |
Annual Cash Flow Conversion Efficiency for BIOCRYST PHARM (2016–2023)
The table below shows the annual cash flow conversion efficiency of BIOCRYST PHARM from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €-455.53 Million | €-95.14 Million | 0.209x | -61.98% |
| 2022-12-31 | €-294.60 Million | €-161.85 Million | 0.549x | -58.65% |
| 2021-12-31 | €-106.99 Million | €-142.16 Million | 1.329x | -81.06% |
| 2020-12-31 | €-19.26 Million | €-135.11 Million | 7.014x | +399.50% |
| 2019-12-31 | €38.25 Million | €-89.58 Million | -2.342x | -24.57% |
| 2018-12-31 | €49.23 Million | €-92.56 Million | -1.880x | -282.78% |
| 2017-12-31 | €83.77 Million | €-41.14 Million | -0.491x | +98.55% |
| 2016-12-31 | €1.58 Million | €-53.44 Million | -33.864x | -- |